Form 4: Evolus CEO Moatazedi Reports PSU Vesting, Tax-Related Stock Sale

Evolus, Inc. CEO David Moatazedi reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• David Moatazedi, President and CEO of Evolus, Inc., acquired 67,489 shares of common stock on March 16, 2026, through the vesting and settlement of performance restricted stock units (PSUs).
• These PSUs were granted on February 7, 2024, with performance conditions based on 2024 and 2025 fiscal year revenue and non-GAAP operating profit, which were certified at 100% achievement.
• On March 17, 2026, Moatazedi sold 116,720 shares of Evolus common stock at a weighted average price of $4.8883 per share.
• The sale was executed under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the vesting of multiple PSU and restricted stock unit awards.
• Following these transactions, Moatazedi beneficially owns 618,369 shares of common stock directly.
• An additional 67,488 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The 100% achievement of performance targets for PSUs is a strong signal of operational success, and the subsequent share sale is a routine tax-related event, not a discretionary disposition.

Positives

• Achievement of 100% of performance targets for the PSUs granted in February 2024, indicating strong company performance in 2024 and 2025.
• The vesting of PSUs at a $0 exercise price represents a direct gain for the executive, aligning executive incentives with shareholder value creation.

Negatives

• A significant number of shares (116,720) were sold, although this was for tax purposes and not a discretionary sale, which could be misinterpreted by some investors.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market risk associated with holding stock.

Future Outlook

The filing indicates that 67,488 PSUs are scheduled to vest on February 7, 2027, contingent on continued service, suggesting an ongoing commitment from the CEO.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity awards, particularly when performance targets are fully met, is a positive indicator of a company's operational and financial health within its sector. The subsequent 'sell to cover' transaction for tax purposes is a standard practice for executives receiving equity compensation and does not typically signal a change in management's long-term outlook or confidence in the company, especially when executed under a pre-arranged 10b5-1 plan.

Comparison to Industry Standards

• The achievement of 100% of performance targets for PSUs is a strong indicator, often outperforming companies that struggle to meet such metrics, suggesting Evolus's performance in 2024-2025 was robust relative to its peers in the aesthetics or specialty pharmaceutical industry.
• The use of a Rule 10b5-1 trading plan for tax-related sales is a common and accepted corporate governance practice, aligning with industry best practices for executive equity compensation management, similar to executives at companies like Allergan (now AbbVie) or Galderma.

Stakeholder Impact

• Shareholders: The achievement of performance targets for executive compensation suggests strong company performance, which is generally positive for shareholder value. The tax-related sale is a routine event and not indicative of a lack of confidence.
• Employees: The CEO's continued equity vesting and service commitment can be seen as a positive signal for company stability and future direction.

Next Steps

• The remaining 67,488 PSUs are scheduled to vest on February 7, 2027, subject to David Moatazedi's continued service.

Key Dates

Recommendation

The filing details a routine executive compensation event involving PSU vesting and a tax-related stock sale under a 10b5-1 plan. While the 100% achievement of performance targets is positive, this Form 4 itself does not introduce new information that would fundamentally alter the investment thesis for Evolus, Inc. It confirms past performance success but doesn't provide new forward-looking guidance or strategic shifts that would warrant a change from a 'hold' position based solely on this filing.

Keywords

Evolus, EOLS, David Moatazedi, Form 4, Insider Trading, Stock Vesting, PSU, Restricted Stock Units, Executive Compensation, Rule 10b5-1, Tax Withholding